Amarillo Biosciences
OTCMKTS:AMARAmarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.
Medicure
OTCMKTS:MCUJFMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Biodexa Pharmaceuticals
NASDAQ:MTPBiodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Wellness Center USA
OTCMKTS:WCUIWellness Center USA, Inc. engages in the healthcare and medical business in the United States and internationally. The company operates through Medical Devices; and Authentication and Encryption Products and Services segments. It is primarily involved in the marketing and distribution of online sports and nutrition supplements. The company also designs, develops, manufactures, markets, and distributes targeted ultraviolet phototherapy devices that include Psoria-Light, which is used in targeted PUVA photochemistry and UVB phototherapy for the treatment of skin conditions, such as psoriasis, vitiligo, atopic dermatitis, seborrheic dermatitis, and leukoderma. In addition, it offers intelligent microparticles, which provide technologies within the security and supply chain management vertical sectors; and ActiveDuty, a data intelligence service comprising proprietary, unprecedented, and actionable technology, which include a suite of analytical tools, such as artificial intelligence and social psychology for industries, companies, and agencies. The company was incorporated in 2010 and is based in Tucson, Arizona.